Telephone sharing button Contact Us mailbox sharing button wuxixdc_info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi XDC Announces Ground-breaking on Singapore Manufacturing Facility to Empower Global Bioconjugates Development
Mar. 19, 2024
WuXi XDC Announces Ground-breaking on Singapore Manufacturing Facility to Empower Global Bioconjugates Development

Shanghai, China, and Singapore, March 19, 2024—WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugates market, today announced a ground-breaking of manufacturing facility in Singapore, poised to bolster global bioconjugation development and manufacturing capabilities. The facility is situated in Singapore Tuas Biomedical Park with a construction area of approximately 22,000 square meters. The facility includes manufacture lines for monoclonal antibody (mAb)intermediate, drug substance (DS) and drug product (DP), Quality Control (QC) labs, and product warehouse. Scheduled to commence operations in 2026, the new site is a testament to our dedication to empowering global clients to accelerate the development and manufacturing of ADCs and XDCs (novel bioconjugates) through one-stop capabilities.

 

 

New Facility Highlights:

 

  • Prime Location and World-class Manufacturing Facility:
    The new facility’s strategic location in Tuas Biomedical Park places it at the nexus of biomedical research and manufacturing, fostering synergies with leading biopharmaceutical entities and research institutes. The Singapore site is designed to include cutting-edge manufacturing lines for monoclonal antibody (mAb)intermediate, drug substance (DS) and drug product (DP). The site will feature comprehensive Quality Control (QC) and product warehouse capabilities, ensuring the highest standards of bioconjugate products quality.

 

  • Advanced Production Capability and Expanded Capacity:
    The new facility will empower clients to advance end-to-end manufacturing at both clinical and commercial stages. Dual function production line for mAb intermediates and bioconjugate drug substance is designed to achieve commercial scale GMP manufacture of mAb intermediates up to 2000 liters, ADCs and other conjugates up to 2000 liters. Conjugation DP production line is equipped with one 10 sqm lyo and two 30 sqm lyos, capable of liquid and lyo drug product manufacturing with annual capacity over 8 million vials. Onsite Manufacturing Science and Technology (MSAT) and QC labs will support seamless technical transfer, full DS and DP release testing and stability study.

 

  • Commitment to Speed and Quality:
    This strategic investment underscores WuXi XDC’s commitment to leveraging Singapore’s thriving biopharmaceutical landscape to build global operation network. Synergized with WuXi XDC’s other sites, it allows for the acceleration of ADCs and other bioconjugates development through fully integrated, one-stop platform, with improved development efficiency. At the Singapore site, WuXi XDC’s industry-leading quality system will ensure the innovative bioconjugate products to be manufactured with high quality.

 

A Vision for the Future

 

Dr. Jimmy Li, CEO of WuXi XDC, shared his vision for the new facility, stating, “The ground-breaking of Singapore facility represents an important milestone in WuXi XDC’s global strategy, offering extensive experience, profound expertise and robust supply chain to our clients worldwide. The strategic all-in-one manufacturing facility will meet our clients’ growing demand for CRDMO services in the field of ADC and XDC. It is a clear indication of our unwavering commitment to supporting the global bioconjugate industry in its quest to develop and manufacture innovative bioconjugate therapies and benefit patients worldwide.”

 

About WuXi XDC

 

WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: https://wuxixdc.com

 

Contacts

 

Investor Inquiry: wuxixdc.ir@wuxibiologics.com
Media Inquiry: wuxixdc_pr@wuxibiologics.com
Business Development: wuxixdc_info@wuxibiologics.com

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?